ABVC BioPharma, Inc. — Operating Income by Fiscal Year
14 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/69874a27-c78c-43bb-916b-13c681f647b9/serie/operating-income
| Fiscal year | Operating Income | Period | Evidence |
|---|---|---|---|
| FY 2025 | $-7.2M | 2025-01-01 – 2025-12-31 | evidence 0001213900-26-023063 |
| FY 2024 | $-4.7M | 2024-01-01 – 2024-12-31 | evidence 0001213900-25-032118 |
| FY 2023 | $-6.8M | 2023-01-01 – 2023-12-31 | evidence 0001213900-25-032118 |
| FY 2022 | $-15.1M | 2022-01-01 – 2022-12-31 | evidence 0001213900-23-025554 |
| FY 2021 | $-11.7M | 2021-01-01 – 2021-12-31 | evidence 0001213900-22-016726 |
| FY 2020 | $-8.5M | 2020-01-01 – 2020-12-31 | evidence 0001213900-21-015729 |
| FY 2019 | $-3.5M | 2019-01-01 – 2019-12-31 | evidence 0001213900-20-012685 |
| FY 2018 | $-2.8M | 2018-01-01 – 2018-12-31 | evidence 0001213900-20-012685 |
| FY 2017 | $-4.1M | 2017-01-01 – 2017-12-31 | evidence 0001213900-19-006364 |
| FY 2016 | $-11.0M | 2015-10-01 – 2016-09-30 | evidence 0001213900-17-005712 |
| FY 2013 | $-177.3k | 2012-10-01 – 2013-09-30 | evidence 0001557234-15-000092 |
| FY 2012 | $-1.1M | 2011-10-01 – 2012-09-30 | evidence 0001557234-15-000080 |
| FY 2011 | $-1.9M | 2010-10-01 – 2011-09-30 | evidence 0001173313-11-000071 |
| FY 2010 | $-1.9M | 2009-10-01 – 2010-09-30 | evidence 0001173313-11-000071 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).